Cargando…

Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants

AIMS: Limited data compared antiarrhythmic drugs (AADs) with concomitant non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients, hence the aim of the study. METHODS AND RESULTS: National health insurance database were retrieved during 2012–17 for study. We excluded patients not...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Victor Chien-Chia, Wang, Chun-Li, Huang, Yu-Chang, Tu, Hui-Tzu, Huang, Yu-Tung, Huang, Chien-Hao, Chen, Shao-Wei, Kuo, Chang-Fu, Hung, Kuo-Chun, Chang, Shang-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227765/ https://www.ncbi.nlm.nih.gov/pubmed/37000581 http://dx.doi.org/10.1093/europace/euad083

Ejemplares similares

Major Bleeding Risk in Atrial Fibrillation Patients Co-Medicated With Non-Vitamin K Oral Anticoagulants and Antipsychotics
por: Chen, Chiung-Mei, et al.
Publicado: (2022)

Safety and Effectiveness of Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study
por: Wang, Chun‐Li, et al.
Publicado: (2019)

Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants
por: Chang, Kuo-Hsuan, et al.
Publicado: (2022)

Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
por: Lee, Hsin‐Fu, et al.
Publicado: (2019)

Efficacy and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study
por: Wang, Chun‐Li, et al.
Publicado: (2018)

Novel oral anticoagulant vs. warfarin in elderly atrial fibrillation patients with normal, mid‐range, and reduced left ventricular ejection fraction
por: Wu, Victor Chien‐Chia, et al.
Publicado: (2020)

Safety and Effectiveness of Direct Oral Anticoagulants vs. Warfarin in Patients With Atrial Fibrillation and Endoscopy-Diagnosed Peptic Ulcer
por: Wang, Chun-Li, et al.
Publicado: (2021)

Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2020)

Resuming anticoagulation in patients with atrial fibrillation experiencing intracranial hemorrhage
por: Wu, Victor Chien-Chia, et al.
Publicado: (2021)

Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants
por: Chan, Yi-Hsin, et al.
Publicado: (2020)

Oral Anticoagulation and Antiarrhythmic Drug Therapy for Atrial Fibrillation
por: Reiffel, James A.
Publicado: (2018)

Knots to untie: anticoagulant and antiarrhythmic therapy after ablation for atrial fibrillation
por: Stazi, Filippo
Publicado: (2020)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
por: Huang, Huei‐Kai, et al.
Publicado: (2020)

Vitamin D and bisphosphonates therapies for osteoporosis are associated with different risks of atrial fibrillation in women: A nationwide population-based analysis
por: Yang, Hung-Yu, et al.
Publicado: (2018)

Risk of Bleeding and Stroke with Oral Anticoagulation and Antiplatelet Therapy in Patients with Atrial Fibrillation in Taiwan: A Nationwide Cohort Study
por: Chen, Pei-Chun, et al.
Publicado: (2015)

Concurrent use of statins decreases major bleeding and intracerebral hemorrhage in non-valvular atrial fibrillation patients taking direct oral anticoagulants—A nationwide cohort study
por: Wu, Hsin-Hsu, et al.
Publicado: (2022)

The CHA(2)DS(2)-VASc Score Predicts Major Bleeding in Non-Valvular Atrial Fibrillation Patients Who Take Oral Anticoagulants
por: Lee, Kuang-Tso, et al.
Publicado: (2018)

Hypoglycemia Associated With Drug–Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors
por: Ray, Chin-Ying, et al.
Publicado: (2021)

Direct Effects of Activation and Inhibition of the Coagulation System on the Atrial Fibrillation Substrate: Is Anticoagulation Antiarrhythmic?
por: Nattel, Stanley
Publicado: (2016)

Emerging Antiarrhythmic Drugs for Atrial Fibrillation
por: Saljic, Arnela, et al.
Publicado: (2022)

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Direct oral anticoagulants and the risk of osteoporotic fractures in patients with non-valvular atrial fibrillation
por: Kuo, Liang-Tseng, et al.
Publicado: (2021)

Surgical volume and outcomes of surgical ablation for atrial fibrillation: a nationwide population-based cohort study
por: Chang, Feng-Cheng, et al.
Publicado: (2023)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Different Renal Function Equations and Dosing of Direct Oral Anticoagulants in Atrial Fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement
por: Wu, Victor Chien-Chia, et al.
Publicado: (2020)

Concomitant diabetes with atrial fibrillation and anticoagulation management considerations
por: Kreutz, Reinhold, et al.
Publicado: (2020)

Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation
por: Xu, Yunwen, et al.
Publicado: (2022)

Comparing Vitamin K Antagonists and Direct Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement: A Meta-Analysis
por: Lee, Wei-Chieh, et al.
Publicado: (2023)

Analysis of Anticoagulation Therapy and Anticoagulation-Related Outcomes Among Asian Patients After Mechanical Valve Replacement
por: Huang, Jo-Ting, et al.
Publicado: (2022)

Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2020)

Insights on Distinct Left Atrial Remodeling Between Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction
por: Kuo, Jen-Yuan, et al.
Publicado: (2022)

Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
por: Giugliano, Robert P
Publicado: (2022)

Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
por: Li, Wenhao, et al.
Publicado: (2022)

Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: Lee, Ki Hong, et al.
Publicado: (2023)

Left ventricular dysfunction in atrial fibrillation and heart failure risk
por: Kuo, Jen‐Yuan, et al.
Publicado: (2020)

Real-world comparison of non-vitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation
por: Kwon, Chang Hee, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pqb5a2tq9rtrvv1n349nkvbss9